Search results
Results from the WOW.Com Content Network
The U.S. Food and Drug Administration has officially approved remdesivir as a treatment for coronavirus, drug manufacturer Gilead Sciences announced Thursday. The Ebola drug was already being used ...
The authorization comes days after data suggested the experimental drug can help patients recover faster. FDA authorizes emergency use of coronavirus drug remdesivir Skip to main content
[61] [62] [63] [108] The US Food and Drug Administration (FDA) approved remdesivir based on the agency's analysis of data from three randomized, controlled clinical trials that included participants hospitalized with mild-to-severe COVID‑19. [63] [108] The FDA granted approval and reissued the revised EUA to Gilead Sciences Inc. [63] The FDA ...
The FDA later clarified that it has not approved any therapeutics or drugs to treat COVID-19, but that studies were underway to see if chloroquine could be effective in treatment of COVID-19. [ 146 ] [ 147 ] Following Trump's claim, panic buying of chloroquine was reported from many countries in Africa, Latin America and South Asia.
Ensitrelvir was approved for emergency use in Japan in November 2022, [9] [4] [5] before gaining full approval in March 2024. [1] It was approved in Singapore in November 2023. [17] In April 2023, ensitrelvir was given a "Fast Track" designation from the US Food and Drug Administration. [18]
The Food and Drug Administration will authorize the emergency use of the antiviral remdesivir on COVID-19 patients as soon as Wednesday, a senior administration official told The New York Times.
Although not statistically significant, among these vaccinated participants, there was a reduction in the risk of COVID‑19 related hospitalization or death from any cause. [14] In December 2021, nirmatrelvir/ritonavir was granted emergency use authorization by the United States Food and Drug Administration (FDA) for the treatment of COVID ...
Earlier this month, the health regulator approved updated COVID-19 vaccines made by Pfizer and Moderna targeting the KP.2 variant. JN.1 was the dominant strain in the United States earlier this year.